Mindfulness-Based Cognitive Therapy (MBCT) for the Prevention of Depression Relapse or Recurrence Using Videoconference
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Objectives: To evaluate the clinical- and cost-effectiveness of two delivery formats of mindfulness-based cognitive therapy (MBCT) - (i) MBCT delivered through eight videoconference group sessions (group MBCT), and (ii) MBCT delivered through a self-help manual plus three low-intensity videoconference group support sessions (supported MBCT self-help) - when added to treatment as usual (TAU; mental health outpatient care), compared with TAU alone, in patients with recurrent depression, either in an acute episode or in remission. We will identify potential predictors and moderators of response and examine psychological mechanisms of change. Study design: Multicentre randomised controlled trial, with pre-post, 6- and 12-months follow-ups. Centres: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat), Hospital Universitario Miguel Servet (Zaragoza), Hospital del Mar (Barcelona), Fundació Centre Higiene Mental Nou Barris (Barcelona), and Hospital General Universitario de Elche (Elche, Alicante). Participants: Adult patients (n=342) with recurrent depression, either in an acute episode or in remission, will be randomly assigned to group MBCT, supported MBCT self-help, or TAU. Primary outcome: transitions between clinically defined states of recurrent depression over the 12-month follow-up (DSM-5). The primary confirmatory transition is from remission to a major depressive episode (relapse/recurrence), whereas the transition from acute depression to remission will be examined as an exploratory objective. Secondary outcomes: depressive symptom severity, negative affect, mental well-being, quality of life, costs, and quality-adjusted life years. Process measures: mindfulness, positive affect, and self-compassion. Main statistical analyses: The primary analysis will use the intention-to-treat (ITT) principle and continuous-time multi-state modelling to estimate transition-specific hazard ratios. Secondary outcomes, predictors, and moderators will be analysed using regression-based approaches. Cost-effectiveness and cost-utility analyses will be conducted from healthcare system and societal perspectives, alongside mediation analyses. Participant experiences will be evaluated using qualitative methods. Conclusions: This study will inform the implementation of two accessible MBCT formats in Spain for preventing depressive relapse/recurrence. The comparison of two delivery formats will provide evidence on effectiveness, cost-effectiveness, scalability, and efficient resource allocation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat
- •Postawienie diagnozy nawracającej depresji (co najmniej 2 poprzednie epizody)
- •Obecny stan: lekka/umiarkowana depresja lub okres remisji (bez objawów)
- •Dostęp do internetu przez smartphone'a lub komputer
- •Umiejętność czytania i mówienia po hiszpańsku
✗ Disqualifies
- •Obecnie ciężka depresja wymagająca natychmiastowej interwencji
- •Obecne lub przeszłe psychozy, choroba afektywna dwubiegunowa typu 1, schizofrenia lub zaburzenia pokrewne
- •Aktualny poważny problem z uzależnieniem od substancji
- •Zaburzenia rozwojowe lub uszkodzenia mózgu
- •Aktualna terapia psychologiczna prowadzona równocześnie z badaniem
- •Brak doświadczenia w obsłudze urządzeń technologicznych
- •Poprzednie zaawansowane praktyki medytacji w ciągu ostatniego roku
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Hospital General Universitario de Elche
Elche, Spain
Parc de Salut Mar
Barcelona, Spain
Fundacio Centre Higiene Mental Nou Barris
Barcelona, Spain
Parc Sanitari Sant Joan de Déu (PSSJD)
Sant Boi de Llobregat, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Trial contact
Jesus Montero, PhD
Jaime Navarrete, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.